Clinical Trial Update: Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update assessing sapanisertib in patients with locally advanced or metastatic urothelial carcinoma of the bladder with TSC1/TSC2 mutati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-11